CA-USERTESTING
UserTesting (NYSE: USER), a leader in video-based human insight , today announced advanced Instant Insight features, powered by machine learning, to help companies expedite the analysis of human insights at the test-level and accelerate time to insights. Using data-automation and proprietary models, the UserTestingⓇ Human Insight Platform can detect patterns and anomalies in the customer data, and automatically surface high-value insights within the Customer Experience Narratives. The latest product updates are designed to help companies uncover key customer perspectives more quickly, so team members can understand where to focus their efforts for greater success. In addition to English and German, UserTesting is now available in French, and customers can test in the French language with access to French speaking contributors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005310/en/
New features in this product release:
Discover Patterns and Key Customer Takeaways More Quickly with Test-Level Instant Insights
UserTesting’s test-level Instant Insight feature utilizes data-driven automation and machine learning models to accelerate post-test analysis by automatically detecting patterns, anomalies, and key insights within customer data across multiple tasks and sessions. Customers can quickly identify important takeaways from their tests while alleviating the burden of lengthy post-test analysis.
Intuitively Navigate and Collaborate with UserTesting
UserTesting’s navigation redesign enables customers to access core functionalities more readily, with a new user interface, folder management, easily accessible resources, and a workspace switcher. Updates make the testing and insight management process more intuitive and accessible for broader team use, enabling scalability for growing teams across organizations. Additionally, IT departments can now manage team access more seamlessly with self-service, single sign-on, providing more governance for enterprise-scale deployments.
A Redesigned Card Sorting Experience
UserTesting has enhanced its card sorting capabilities within the UserTesting Human Insight Platform so users can view video feedback alongside card sorting metrics and gather a complete understanding of contributors’ mental models with this streamlined solution. Companies can build navigation or sitemaps based on customer expectations and behaviors, and describe categories to drive better engagement. This helps companies save costs and adapt to rapidly changing customer needs, or changes to their respective businesses, with timely feedback of how digital properties are organized and used.
En français … UserTesting
UserTesting is now available in French for both customer and contributor experiences. Companies looking to get feedback from French-speaking consumers can now do so with the UserTesting Human Insight Platform, as tests can be conducted in French, with French-speaking contributors, giving organizations the ability to target and connect with more people around the world.
Now Supports Native Video/Audio Testing
For companies wanting to test sensitive media content with greater efficiency, UserTesting enables customers to securely upload audio, video, and other media assets directly onto the Human Insight Platform with its new native media asset testing feature. Companies can gather contributor feedback easily on unreleased assets, like video and audio files, before launching them to the public.
“More than ever, it’s imperative that companies know how their customers feel, and why. UserTesting is continuously innovating its platform to help companies gain actionable insights so they can make smarter and faster business decisions,” said Kaj van de Loo, CTO at UserTesting. “UserTesting’s data-driven automation helps customers speed up analysis of video feedback, so they can make decisions quicker than ever. The platform helps companies optimize the use of human insights, so that they can better understand what is driving customer behavior, and adapt to any changes in the market.”
UserTesting will be hosting a webinar highlighting its latest product release on August 3 at 11:00 a.m. PT/2:00 p.m. ET. Register for the webinar here .
About UserTesting
UserTesting (NYSE: USER) has fundamentally changed the way organizations get insights from customers with fast, opt-in feedback and experience capture technology. The UserTesting Human Insight Platform taps into our global network of real people and generates video-based recorded experiences, so anyone in an organization can directly ask questions, hear what users say, see what they mean, and understand what it’s actually like to be a customer. Unlike approaches that track user behavior then try to infer what that behavior means, UserTesting reduces guesswork and brings customer experience data to life with human insight. UserTesting has approximately 2,500 customers, including more than half of the world’s top 100 most valuable brands according to Forbes. UserTesting is headquartered in San Francisco, California. To learn more, visit www.usertesting.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005310/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
